Contract Drug Maker V-Ensure Gets Rs 130 Cr From Investcorp, Tanas Capital

E-Ensure Pharma Technologies, which is into contract drug manufacturing, has raised Rs 130-crore (USD 17.5 million) from global alternative investment firm Investcorp and Asia-based private investment firm Tanas Capital.

For Investcorp this is the third healthcare investment in the country and its first in the pharmaceutical sector, the firm said in a statement.

New capital will enable V-Ensure to further expand its product development and marketing capabilities globally to North America and Europe, and other global markets for the development and launch of its products.

Founded in 2010, V-Ensure is into specialty pharmaceutical formulations focused on complex generics for regulated markets. Its core competence lies in developing complex molecules for regulated markets.

It also specializes in developing right strategies to obtain regulatory approvals for commercialization of these molecules by managing all necessary processes and documentation required by the regulator.

V-Ensure has developed solid oral, liquid oral and injectable products for over 45 clients across Europe, North America, China, Australia and Brazil, Satyanarayana Vemula, chief executive of V-Ensure said.

Investcorp has been active in the mid-market private equity space in the country since 2019, investing across the healthcare, businesses services, financial services, consumer & retail, and technology sectors.

Its investments over the last four years include Nephroplus, Wingreens, Intergrow Brands, Bewakoof.com, Freshtohome, Zolostays, Incred, Citykart, ASG Eye Hospital, Unilog, Xpressbees, and Safari Industries.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor